Integrated technology platform protein kinases for drug development in oncology

被引:8
作者
Sachsenmaier, C [1 ]
Schächtele, C [1 ]
机构
[1] ProQinase GmbH, D-79106 Freiburg, Germany
关键词
D O I
10.2144/Oct0213
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Protein kinases are among the most promising targets for drug discovery and development, mostly in oncology but also in other fields such as inflammation, Alzheimer, and infectious diseases. The Integrated Technology Platform Protein Kinases was designed as a comprehensive tool for drug discovery in the field of oncology. It combines modules for the identification and validation of novel target protein kinases, a unique panel of active recombinant protein kinases, high-throughput screening, selectivity profiling, cellular testing, and in vivo tumor models. Here we give an overview of the Integrated Technology Platform Protein Kinases as well as data that validate each module.
引用
收藏
页码:101 / 106
页数:6
相关论文
共 1 条
[1]   Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug [J].
Capdeville, R ;
Buchdunger, E ;
Zimmermann, J ;
Matter, A .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (07) :493-502